BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

824 related articles for article (PubMed ID: 26617827)

  • 1. Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors.
    Zhang L; Qiu M; Jin Y; Ji J; Li B; Wang X; Yan S; Xu R; Yang D
    Int J Clin Exp Pathol; 2015; 8(9):11084-91. PubMed ID: 26617827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability.
    Cho J; Lee J; Bang H; Kim ST; Park SH; An JY; Choi MG; Lee JH; Sohn TS; Bae JM; Kang WK; Kim S; Kim KM
    Oncotarget; 2017 Feb; 8(8):13320-13328. PubMed ID: 28076847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between expression of IGFBP7 and clinicopathological variables in gastric cancer.
    Sato Y; Inokuchi M; Takagi Y; Otsuki S; Fujimori Y; Yanaka Y; Kobayashi K; Higuchi K; Kojima K; Kawano T
    J Clin Pathol; 2015 Oct; 68(10):795-801. PubMed ID: 26043748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
    Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
    Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of pyruvate dehydrogenase is an independent prognostic marker in gastric cancer.
    Sun XR; Sun Z; Zhu Z; Guan HX; Li CY; Zhang JY; Zhang YN; Zhou H; Zhang HJ; Xu HM; Sun MJ
    World J Gastroenterol; 2015 May; 21(17):5336-44. PubMed ID: 25954108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of PD-L1 and PD-L2 in breast cancer.
    Baptista MZ; Sarian LO; Derchain SF; Pinto GA; Vassallo J
    Hum Pathol; 2016 Jan; 47(1):78-84. PubMed ID: 26541326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programmed death-ligand 1 expression in gastric adenocarcinoma is a poor prognostic factor in a high CD8+ tumor infiltrating lymphocytes group.
    Chang H; Jung WY; Kang Y; Lee H; Kim A; Kim HK; Shin BK; Kim BH
    Oncotarget; 2016 Dec; 7(49):80426-80434. PubMed ID: 27741514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer.
    Sepesi B; Cuentas EP; Canales JR; Behrens C; Correa AM; Vaporciyan A; Weissferdt A; Kalhor N; Moran C; Swisher S; Wistuba I
    Semin Thorac Cardiovasc Surg; 2017 Autumn; 29(3):408-415. PubMed ID: 29195578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroblast growth factor receptor 4 protein expression and clinicopathological features in gastric cancer.
    Chen H; Shen DP; Zhang ZZ; Liu JH; Shen YY; Ni XZ
    World J Gastroenterol; 2015 Feb; 21(6):1838-44. PubMed ID: 25684949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased expression of DLX2 correlates with advanced stage of gastric adenocarcinoma.
    Tang P; Huang H; Chang J; Zhao GF; Lu ML; Wang Y
    World J Gastroenterol; 2013 May; 19(17):2697-703. PubMed ID: 23674878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival.
    He XX; Ding L; Lin Y; Shu M; Wen JM; Xue L
    J Clin Pathol; 2015 May; 68(5):374-80. PubMed ID: 25731189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas.
    Mukaigawa T; Hayashi R; Hashimoto K; Ugumori T; Hato N; Fujii S
    J Surg Oncol; 2016 Jul; 114(1):36-43. PubMed ID: 27111278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low CA II expression is associated with tumor aggressiveness and poor prognosis in gastric cancer patients.
    Hu X; Huang Z; Liao Z; He C; Fang X
    Int J Clin Exp Pathol; 2014; 7(10):6716-24. PubMed ID: 25400751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of TFF3 protein and Her-2/neu status in patients with gastric adenocarcinoma.
    Xu CC; Yue L; Wei HJ; Zhao WW; Sui AH; Wang XM; Qiu WS
    Pathol Res Pract; 2013 Aug; 209(8):479-85. PubMed ID: 23822993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of HER-2 Protein is a High-Risk Factor for Patients with Surgically-Resected Stage T3 Gastric Adenocarcinoma.
    Zhang Z; Wang B; Huang G; Wang R; Song J; Lin S; Wang W; Jiang Y; Huang Q; Wang L
    Clin Lab; 2017 Jan; 63(1):115-125. PubMed ID: 28164509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Ki67 Expression has Prognostic Value in Surgically-Resected T3 Gastric Adenocarcinoma.
    Huang G; Chen S; Wang D; Wang R; Lin L; Chen S; Wang L; Huang Q
    Clin Lab; 2016; 62(1-2):141-53. PubMed ID: 27012044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.
    Kawazoe A; Kuwata T; Kuboki Y; Shitara K; Nagatsuma AK; Aizawa M; Yoshino T; Doi T; Ohtsu A; Ochiai A
    Gastric Cancer; 2017 May; 20(3):407-415. PubMed ID: 27629881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.
    Chowdhury S; Veyhl J; Jessa F; Polyakova O; Alenzi A; MacMillan C; Ralhan R; Walfish PG
    Oncotarget; 2016 May; 7(22):32318-28. PubMed ID: 27086918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection.
    Eto S; Yoshikawa K; Nishi M; Higashijima J; Tokunaga T; Nakao T; Kashihara H; Takasu C; Iwata T; Shimada M
    Gastric Cancer; 2016 Apr; 19(2):466-471. PubMed ID: 26210691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.
    Cooper WA; Tran T; Vilain RE; Madore J; Selinger CI; Kohonen-Corish M; Yip P; Yu B; O'Toole SA; McCaughan BC; Yearley JH; Horvath LG; Kao S; Boyer M; Scolyer RA
    Lung Cancer; 2015 Aug; 89(2):181-8. PubMed ID: 26024796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.